ホーム › 卵巣がん › オハイオ › Cincinnati
Cincinnati、OHにおける卵巣がんの臨床試験
Cincinnatiとその周辺地域（約30マイル以内）の拠点で、卵巣がんに関する19件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
被験者募集中第2相
- Good Samaritan Hospital - Cincinnati, Cincinnati
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
被験者募集中第2相
- University of Cincinnati Medical Center. /ID# 278925, Cincinnati
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
被験者募集中第2相
- Site 0147 - Trihealth Cancer Institute - Harold and Eugen, Cincinnati
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
被験者募集中第2相
- Research Site, Cincinnati
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
被験者募集中第3相
- University of Cincinnati Medical Center, Cincinnati
- Oncology Hematology Care Inc, Cincinnati
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
被験者募集中第3相
- University of Cincinnati Medical Center ( Site 0042), Cincinnati
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
被験者募集中第2相
- Oncology Hematology Care, Inc, Cincinnati
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
被験者募集中第3相
- St Elizabeth Healthcare, Edgewood · 8マイル先
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
被験者募集中第1/2相
- Christ Hospital, Cincinnati
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
被験者募集中第3相
- University of Cincinnati Medical Center ( Site 0090), Cincinnati
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
被験者募集中第1/2相
- Cincinnati Children's Hospital Medical Center, Cincinnati
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
被験者募集中第1相
- St. Elizabeth Healthcare, Edgewood · 8マイル先
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
被験者募集中
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Bethesda North Hospital, Cincinnati
- 他3件
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
被験者募集中第3相
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Bethesda North Hospital, Cincinnati
- TriHealth Cancer Institute-Westside, Cincinnati
- 他1件
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Oncology Hematology Care Primary, Cincinnati
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
被験者募集中第2/3相
- St. Elizabeth Medical Center, Edgewood · 8マイル先
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
被験者募集中第2相
- St. Elizabeth Medical Center - Edgewood /ID# 272113, Edgewood · 8マイル先
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
被験者募集中第3相
- University of Cincinnati Medical Center, Cincinnati
- TriHealth Cancer Institute - Good Samaritan Hospital, Cincinnati
- TriHealth Cancer Institute- Thomas Comprehensive Care Center, Cincinnati
- 他1件
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Cincinnati
他の都市における卵巣がんの試験
- Houston, TX89件の研究
- New York City, NY69件の研究
- Boston, MA61件の研究
- Los Angeles, CA50件の研究
- Nashville, TN49件の研究
- Arlington, VA46件の研究
- Philadelphia, PA44件の研究
- Columbus, OH39件の研究
- St. Louis, MO38件の研究
- Chicago, IL36件の研究
- San Antonio, TX31件の研究
- Cleveland, OH30件の研究
Cincinnatiにおける他の研究
- 非小細胞肺癌35件の研究
- がん（全種類）27件の研究
- 乳がん25件の研究
- 心不全24件の研究
- 大腸癌21件の研究
- 急性骨髄性白血病20件の研究
- 転移性癌20件の研究
- 肺がん19件の研究
- 肥満症19件の研究
- 前立腺がん18件の研究
- 多発性骨髄腫17件の研究
- 悪性黒色腫17件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。